Abstract
1. This placebo-controlled study assessed once daily sustained-release (SR) diltiazem, 200 and 300 mg, in 182 stable angina patients with positive exercise test. 2. Exercise testing was performed at baseline after a 7 day placebo run-in period, and repeated after 7 days of treatment, 25.0 +/- 0.1 h postdose. 3. Diltiazem (200 and 300 mg) produced respectively a 68% and a 64% decrease in weekly angina episodes, and placebo a 15% decrease (P < 0.05). Similarly, both dose levels produced a 70% decrease in nitroglycerin consumption, whereas no difference was obtained with placebo (P < 0.01). The increase in time to ischaemic threshold was significantly superior for 200 mg and 300 mg diltiazem when compared with placebo (75.2 and 91.5 s respectively vs 47.0 s) (P < 0.05); increase in time to anginal threshold was also significantly greater for diltiazem when compared with placebo (84.6 and 85.9 s respectively vs 43.9 s) (P < 0.05). 4. Only one patient experienced worsening of angina and had to be withdrawn from the study. 5. This study demonstrates 200 and 300 mg SR diltiazem is effective when given once-a-day in the prophylaxis of stable exertional angina. This once daily formulation should improve patients' compliance and comfort.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Buckley M. M., Grant S. M., Goa K. L., McTavish D., Sorkin E. M. Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs. 1990 May;39(5):757–806. doi: 10.2165/00003495-199039050-00009. [DOI] [PubMed] [Google Scholar]
- Emanuelsson H., Ake H., Kristi M., Arina R. Effects of diltiazem and isosorbide-5-mononitrate, alone and in combination, on patients with stable angina pectoris. Eur J Clin Pharmacol. 1989;36(6):561–566. doi: 10.1007/BF00637736. [DOI] [PubMed] [Google Scholar]
- Klinke W. P., Juneau M., Grace M., Kostuk W. J., Pflugfelder P., Maranda C. R., Warnica W., Chin C., Annable L., Dempsey E. E. Usefulness of sustained-release diltiazem for stable angina pectoris. Am J Cardiol. 1989 Dec 1;64(19):1249–1252. doi: 10.1016/0002-9149(89)90562-6. [DOI] [PubMed] [Google Scholar]
- Posma J. L., van Dijk R. B., Lie K. I. Sustained-release diltiazem versus metoprolol in stable angina pectoris. Eur Heart J. 1989 Oct;10(10):923–927. doi: 10.1093/oxfordjournals.eurheartj.a059403. [DOI] [PubMed] [Google Scholar]
- Vliegen H. W., van der Wall E. E., Kragten J. A., Holwerda N. J., Schenkel W. M., Muijs van de Moer W. M., ten Kate J. B., Mulder P. G., Bruschke A. V. Comparison of diltiazem standard formulation and diltiazem controlled release in patients with stable angina pectoris: a randomized, double-blind, cross-over, multicenter study. J Cardiovasc Pharmacol. 1993 Apr;21(4):552–559. doi: 10.1097/00005344-199304000-00007. [DOI] [PubMed] [Google Scholar]
- Weiner D. A., Cutler S. S., Klein M. D. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol. 1986 Jan 1;57(1):6–9. doi: 10.1016/0002-9149(86)90941-0. [DOI] [PubMed] [Google Scholar]